Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership
All
13F
13D/G
Other
Tags
CC transcript
|
|
GSK plc (GSK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/27/2021 |
GN
| Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 |
| 01/12/2021 |
GN
| Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 |
| 10/06/2020 |
GN
| Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19 |
| 09/08/2020 |
GN
| Biopharma Leaders Unite to Stand with Science |
| 08/31/2020 |
GN
| Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment |
| 07/15/2020 |
GN
| Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK |
| 05/18/2020 |
GN
| Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature |
| 04/06/2020 |
GN
| GSK and Vir Biotechnology enter collaboration to find coronavirus solutions |
| 03/04/2019 |
GN
| New Research: Key Drivers of Growth for GlaxoSmithKline plc, nVent Electric, Dana, FMC, Qualys, and Affiliated Managers Group — Factors of Influence, Major Initiatives and Sustained Production |
| 12/03/2018 |
GN
| Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Tesaro, Inc. (TSRO) on Behalf of Stockholders and Encourages TSRO Investors to Contact the Firm |
| 12/03/2018 |
GN
| GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company |
| 10/17/2018 |
GN
| NeuroMetrix Reports Q3 2018 Financial Results |
| 09/26/2018 |
GN
| New Research Coverage Highlights Sanofi, Amdocs, GlaxoSmithKline plc, BT Group, Sociedad Quimica y Minera S.A, and ARMOUR Residential REIT — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 07/19/2018 |
GN
| NeuroMetrix Reports Q2 2018 Financial Results |
| 07/18/2018 |
GN
| Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts |
| 06/11/2018 |
GN
| Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self-renewing, and Capable of Persistent Anti-Tumor Effects |
| 06/08/2018 |
GN
| New Research: Key Drivers of Growth for BP p.l.c, Petroleo Brasileiro S.A.- Petrobras, Transocean, GlaxoSmithKline plc, Noble, and Grupo Televisa S.A. — Factors of Influence, Major Initiatives and Sustained Production |
| 06/04/2018 |
GN
| Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells |
| 06/04/2018 |
GN
| Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO |
| 06/02/2018 |
GN
| Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile |
| 05/16/2018 |
GN
| Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting |
| 05/09/2018 |
GN
| Adaptimmune Reports First Quarter 2018 Financial Results and Business Update |
| 04/19/2018 |
GN
| NeuroMetrix Reports Q1 2018 Financial Results |
| 04/16/2018 |
GN
| Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting |
| 03/27/2018 |
GN
| Consolidated Research: 2018 Summary Expectations for BP p.l.c, Gerdau S.A, GlaxoSmithKline plc, Suncor Energy, TCF Financial, and BRF S.A — Fundamental Analysis, Key Performance Indications |
| 03/15/2018 |
GN
| Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells |
| 03/05/2018 |
GN
| Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018 |
| 01/25/2018 |
GN
| NeuroMetrix Reports Q4 and Full Year 2017 Financial Results |
| 01/17/2018 |
GN
| NeuroMetrix and GlaxoSmithKline Consumer Healthcare Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology |
| 01/08/2018 |
GN
| Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company |
| 12/11/2017 |
GN
| Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study |
| 11/10/2017 |
GN
| Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting |
| 11/09/2017 |
GN
| NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune's SPEAR T-Cell Therapy |
| 11/06/2017 |
GN
| Adaptimmune marks Official Opening of U.K. Headquarters |
|
|
|